Artelo Biosciences (ARTL) Cash from Financing Activities (2015 - 2025)

Artelo Biosciences (ARTL) has reported Cash from Financing Activities for 11 consecutive years, with $1.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash from Financing Activities rose 2719.3% year-over-year to $1.6 million; the TTM figure through Dec 2025 stood at $6.9 million (up 6031.25% YoY), while the FY2025 annual figure was $6.9 million, up 6031.25% from the prior year.
• Cash from Financing Activities fell to $1.6 million in Q4 2025 per ARTL's latest filing, from $3.4 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $18.3 million in Q4 2021 and bottomed at -$134000.0 in Q2 2022.
• Historically, Cash from Financing Activities has averaged $2.8 million across 5 years, with a median of $535000.0 in 2023.
• Annual changes were most pronounced in 2021 — Cash from Financing Activities surged 254873.68% — and 2023, when it tumbled 76.12%.
• Artelo Biosciences' Cash from Financing Activities stood at $18.3 million in 2021, then plunged by 99.27% to $134000.0 in 2022, then sank by 76.12% to $32000.0 in 2023, then soared by 78.12% to $57000.0 in 2024, then jumped by 2719.3% to $1.6 million in 2025.
• Business Quant data shows ARTL's Cash from Financing Activities at $1.6 million in Q4 2025, $3.4 million in Q3 2025, and $1.8 million in Q2 2025.